Core Viewpoint - The article discusses the announcement of a project by Ningxia Zhongke Biological New Materials Co., Ltd. to produce 110,900 tons of bio-fermentation products annually, highlighting the company's technological upgrades and production capabilities in the bio-manufacturing sector [1]. Project Overview - Project Name: Annual production of 110,900 tons of bio-fermentation products - Construction Unit: Ningxia Zhongke Biological New Materials Co., Ltd. - Nature of Construction: Technological upgrade - Industry Category: C2710 Chemical raw materials and pharmaceutical manufacturing - Investment: 100.89 million yuan - Location: Shizuishan Economic and Technological Development Zone - Land Area: 387,309.18 m², utilizing existing facilities without new land acquisition [2]. Construction Scale - The project includes four flexible production lines: 1. **Long-chain dicarboxylic acid production line**: Annual capacity of 18,000 tons, producing various dicarboxylic acids [3]. 2. **Bio-fermentation functional products production line**: Annual capacity of 5,100 tons, including D-chiro-inositol, coenzyme Q10, and DHA algae oil [4]. 3. **Bio-food production line**: Annual capacity of 63,000 tons, producing calcium propionate and L-malic acid [5]. 4. **Amino acid products production line**: Annual capacity of 24,800 tons, producing various amino acids [6]. Technological Upgrade Scope - The upgrade encompasses fermentation workshops, extraction workshops, refining workshops, drying workshops, liquid bio-fertilizer workshops, tank areas, and power centers [7]. Company Background - Ningxia Zhongke Biological New Materials Co., Ltd. was established on June 2, 2017, with a registered capital of 1.3 billion yuan. The company is involved in the production of feed additives, food additives, fertilizers, and bio-based materials [8]. Financial Performance - The company reported revenue of 345 million yuan and a net loss of 539 million yuan during the reporting period. To address its debt crisis, the company entered pre-restructuring in May 2024, with government support extended until the end of 2024 [9]. - In the first quarter of 2025, the company achieved total revenue of 93.82 million yuan, a year-on-year increase of 74.08%, but still reported a net loss of 64.08 million yuan [11].

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the "14th Five-Year Plan" period, discussing innovative technologies and products that can sustain the industry's vitality [1]. Group 2: Organizers and Highlights - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. - Key highlights include forums on biomanufacturing trends, youth innovation sharing, project roadshows, and participation from leading enterprises, top universities, and investment institutions [4]. Group 3: Agenda and Special Activities - The first day features a closed-door high-level seminar focusing on biomanufacturing development trends and growth points, inviting 30 industry leaders and experts [7]. - The second and third days will include a macro forum on biomanufacturing, specialized sub-forums on green chemicals, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. Group 4: Focus Areas in Sub-Forums - Sub-forum topics include the development of bio-based chemicals, green manufacturing technologies for fine chemicals, and the use of non-food raw materials for high-value product development [11]. - AI applications in biomanufacturing will also be discussed, including the use of AI for enzyme discovery and industrial fermentation process control [11].

资本事件 | 三井化学 【SynBioCon】 获 悉，6月19日， 三井化学 宣布通 过321FORCE™全球 创新基金（321FORCE）投资了一家总部位于英国伦敦 的 细胞培养替代脂肪 初创Hoxton Farms 。 而就在 今年3月， Hoxton Farms正展开 与 日本住友公司 Sumitomo Corporation达成战略合作，共同推动培育脂肪 Hoxton Fat在 日本及亚太市场 的 应用。 在应用方面 ，双 方将Hoxton Fat整合到多种食品中， 从汤和酱汁到咸味糕点和加工肉类 。 资质方面 ，公司将与日本监管机构合作，在日本细胞农业协会 （JACA）的协助下获得相关的食品安全 批准。 市场方面，亚洲肉类需求增长对健康与食品安全的影响 。 随着收入增长、城市化进程加快及人口增长，亚洲消费者的饮食结构正在发生变化，高热量、高饱和脂肪的食品摄入量不断上升，肥胖问题日益严重。亚太 地区超过40%的成年人超重或肥胖，因肥胖及相关疾病导致的医疗支出占比高达12%。 与此同时， 亚洲的肉类需求预计到2050年将增长78% 。供应链不稳定、气候变化及疾病传播进一步加剧了食品安全危机。在这一背景 ...

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the "14th Five-Year Plan" period, discussing innovative technologies and products that can sustain the industry's vitality [1]. Group 2: Organizing Institutions - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. Group 3: Highlights of the Conference - The conference will feature forums and closed-door activities to gain insights into the development trends of biomanufacturing during the "14th Five-Year Plan" [4]. - There will be over 100 financing project roadshows to discover new cooperation opportunities [4]. - Key industry leaders, top universities, and capital from various sectors will gather to discuss and share insights [4]. Group 4: Agenda and Special Activities - The first day will include a closed-door seminar focusing on the development trends and growth points of biomanufacturing, inviting 30 industry leaders and experts [7]. - The second and third days will feature a macro forum on biomanufacturing, discussing the overall trends and progress in the industry [10]. Group 5: Specialized Forums - Specialized forums will cover topics such as green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. - The forums will address various key topics, including the development of bio-based chemicals, green manufacturing technologies, and the application of AI in biomanufacturing processes [11]. Group 6: Technology and Innovation - The conference will showcase technological achievements and innovations in the field of biomanufacturing, inviting participation from research institutions and enterprises [10]. - There will be a focus on discovering potential teams and technologies in biomanufacturing, with over 30 presentations planned to facilitate efficient communication and collaboration [10].

Group 1 - Universities are a major source of technological breakthroughs and have maintained a 70% share of national science and technology awards [1] - Despite improvements in technology transfer rates, many research outcomes remain unutilized in the market [1] - Jiangsu Province's Yixing City has implemented various support plans to facilitate the transformation of scientific research into industrial applications, particularly in synthetic biology [2][3] Group 2 - The Yixing Food and Biotechnology Research Institute, established with the help of Jiangnan University, aims to bridge the gap between laboratory results and market applications [2][3] - The research institute has successfully engaged 14 academicians as scientific advisors and 19 as discipline leaders within three years [2] - The institute's laboratories focus on integrating biotechnology with food technology, enhancing the local food biotechnology industry [2][3] Group 3 - Jiangnan University has collaborated with local enterprises to transition from traditional energy to biotechnology, leading to advancements in biomanufacturing technologies [3] - The research institute has provided over 20 technical services to local companies, generating a total contract value exceeding 16 million yuan [3] - The institute has also facilitated the establishment of eight biotechnology and food technology companies in Yixing [3] Group 4 - The favorable business environment in Yixing has attracted companies like Wuxi Licheng Medical Nutrition Co., which has achieved over 100 million yuan in annual sales [4] - The local government is promoting "alumni economy" and enhancing industry-academia-research collaboration to strengthen high-end talent aggregation [4] - Yixing's life and health industry is rapidly developing, with 50 large-scale enterprises reported in the sector [4]

近年来，生物制造已作为多数国家提升经济竞争力的着力点，也是我国继绿色制造、智能制造后，推进制造强国建设的又一重要抓手。同时，各地政府 地区通过结合自身优势力争实现合成生物"研发－转化－产业—集群"协同发展，发挥新质生产力 作用。 8月20-22日 将于 浙江·宁波 举 办 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2 025 ) 。大会 聚焦" 1+4 " ： AI+生 物智造 这一大热门赛道； 绿色化工与新材料、 未来食品、未来农业和美妆原料四大应用领域 ，邀请国 际领先企业、代表性产业化专家、政府、园 区、资本、协会和联盟等各方共探 "十五五"生物制造产业发展趋势 ； 哪些革新技术和产品将给生物制造产业带来持续的生命力 ； 并致力于 促进科技 成果转移转化 、 产品 规模 化与人才挖掘 。 一、组织机构 主办单位： 宁波德泰中研信息科技有限公司（ DT 新材料） 协办 单位： 宁波酶赛生物工程有限公司 二、大会亮点 三、大会日程 亮点一 ： 大会论坛、闭门活动洞察"十五五"生物制造发展趋势！探索新产品、新技术、新落地、 新合作！ 亮点二： 青年创新技术与价值分享、人才对接与合作！ 亮 ...

Core Viewpoint - JINBO Biotech is the only company in China with three Class III certifications for injectable recombinant humanized collagen, leading the development of innovative medical materials and aiming to become a global leader in life materials [1][2]. Group 1: Product Development and Innovation - The company has successfully developed a full range of recombinant type III humanized collagen products, including freeze-dried fibers, solutions, and gels, establishing a comprehensive product system [2][3]. - JINBO Biotech's research has led to the first large-scale production of recombinant type III humanized collagen with a 164.88° triple helix structure, marking a significant breakthrough in the field [2][3]. - The company emphasizes the importance of eliminating immunogenicity and achieving large-scale production of collagen materials to meet safety and efficacy demands in medical applications [2][3]. Group 2: Research and Development Investment - In 2024, JINBO Biotech plans to invest 123 million yuan in R&D, an increase of 18.71% year-on-year, representing 8.52% of its revenue [4]. - The company is focusing on various types of humanized collagen projects, with some products already entering clinical trials [4][5]. Group 3: International Collaboration and Standards - JINBO Biotech collaborates with leading companies like L'Oréal to enhance global recognition of its technologies and promote international market penetration [5]. - The company has taken a leading role in establishing international standards for medical devices made from bioengineered materials, enhancing China's technological influence in this field [5]. Group 4: Technological Advancements and AI Integration - The company has established a FAST database for humanized collagen, significantly improving R&D efficiency through AI technology, reducing the time for data screening from one month to one day [6]. - JINBO Biotech integrates advanced technologies such as AlphaFold for protein structure prediction and has established a smart laboratory to ensure data reliability and enhance R&D capabilities [6].

Core Viewpoint - Suzhou Yike Biotechnology Co., Ltd. is the world's first company to possess PCT patents for producing PHA biodegradable plastic resins, focusing on high-performance eco-friendly materials for food and medical packaging [1][3]. Group 1: Company Overview - Suzhou Yike Biotechnology Co., Ltd. held a project signing ceremony on June 12 and obtained its business license on the same day [1]. - The company aims to establish a research and development center and production base in Taihu New City, targeting an annual production capacity of 10,000 tons, with a phased construction plan [3]. Group 2: Market Potential - The global market for PHA microspheres and PHA bioplastics was valued at $18.8 million in 2023 and is projected to reach $36.7 million by 2030, with a compound annual growth rate (CAGR) of 10.1% from 2024 to 2030 [3]. - The top five global PHA manufacturers hold over 85% of the market share, indicating a concentrated industry [3]. Group 3: Industry Challenges - PHA materials have advantages in biodegradability and biocompatibility over traditional plastics, but their production costs remain higher, with raw material costs accounting for 60% of expenses [3]. - The ex-factory price of PHA products is approximately 40,000 yuan per ton, which limits industrial production and application [3]. Group 4: Future Outlook - The company plans to drive innovation in technology and aims to become a leading player in the bioplastics industry with a global presence [3]. - The industry is expected to see increased interest as more companies accelerate their efforts to develop low-cost raw materials and improve production efficiency [4].

14家企业和机构将首发首展新产品、新技术，其中全球或全国首发的有7项。 "我原来是在高校做基础研究的，现在开始投身于应用，其实像我们高校的科研成果转化到市场还要涉及很多流程、手续，需要专业的机构来连 接。"在上交会长三角国创中心展台，来自华中师范大学的教授冯玲玲对第一财经说。 这并不是冯玲玲第一次来上海参加大型的展会，不过作为上交会的"萌新"选手，她还是希望借助该平台把他们的技术推向全国乃至世界。 和冯玲玲一样首次参加上交会的上海听介科技有限公司带来了混合智能通用设计平台，该公司创始人佘汀涛对记者说，除了希望通过上交会来认识 更多的投资人，还希望能接触到更多海外的客户，能带着他们的AI产品出海。 上交会的全称是中国（上海）国际技术进出口交易会，作为我国首个以技术作为展示和交易标的的国家级、国际性、综合性展会，6月11日~13日举 行的上交会也是技术贸易领域展示先进技术、链接创新资源、深化国际交流合作的重要平台。 "今年展会设4个专业技术展区，技术交易服务和技术交易促进活动2个功能区域，总展出面积3.5万平方米。14家企业和机构将首发首展新产品、新 技术，其中全球或全国首发的有7项。"上海市商务委主任朱民介绍。 ...

Group 1 - The Jiangsu Province Strategic Emerging Industry Special Fund, initiated by Changzhou Investment Group, has a total scale of 8.5 billion and has officially entered the investment phase [1] - The Changzhou Future Industry Angel Fund, as a key component of the provincial strategic emerging fund cluster, has selected Suzhou Yuanhe Holdings as the fund management institution [1] - The fund focuses on key future industry sectors such as synthetic biology, third-generation semiconductors, artificial intelligence, low-altitude economy, and aerospace development, aligning with the "51010" strategic emerging industry cluster and "1650" industrial system [1]